ResearcherInha UniversityActive in the last 2 years
Ye Jin Cho
Matched on OpenAlex author ID A5070123449. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 3
- Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. Co-author DOI 10.3892/ijmm.2024.5458↗
- Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2023.114716↗
- A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. Co-author PMID 36225647↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Soyeon Ko · 3 shared papers, 2022–2025 · strength 0.50
- Paper Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. DOI 10.3892/ijmm.2024.5458↗
- Paper Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancr… DOI 10.1016/j.biopha.2023.114716↗
- Paper A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. PMID 36225647↗
- Kyung Hee Jung · 3 shared papers, 2022–2025 · strength 0.50
- Paper Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. DOI 10.3892/ijmm.2024.5458↗
- Paper Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancr… DOI 10.1016/j.biopha.2023.114716↗
- Paper A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. PMID 36225647↗
- Soon‐Sun Hong · 2 shared papers, 2023–2025 · strength 0.37
- Paper Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer. DOI 10.3892/ijmm.2024.5458↗
- Paper Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancr… DOI 10.1016/j.biopha.2023.114716↗
- Minhee Park · 1 shared paper, 2025 · strength 0.22
- Ji Eun Lee · 1 shared paper, 2023 · strength 0.15
- Soon‐Sun Hong · 1 shared paper, 2022 · strength 0.13
- Sungwoo Hong · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.